BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Malinowska B, Baranowska-Kuczko M, Kicman A, Schlicker E. Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19. Int J Mol Sci 2021;22:1986. [PMID: 33671463 DOI: 10.3390/ijms22041986] [Cited by in Crossref: 1] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Q, Melchert PW, Markowitz JS. In vitro evaluation of the impact of Covid-19 therapeutic agents on the hydrolysis of the antiviral prodrug remdesivir. Chem Biol Interact 2022;365:110097. [PMID: 35964681 DOI: 10.1016/j.cbi.2022.110097] [Reference Citation Analysis]
2 Appendino G, Taglialatela-scafati O, Muñoz E. Cannabidiol (CBD) From Non-Cannabis Plants: Myth or Reality? Natural Product Communications 2022;17:1934578X2210988. [DOI: 10.1177/1934578x221098843] [Reference Citation Analysis]
3 Ashtar Nakhaei N, Najarian A, Farzaei MH, Norooznezhad AH. Endothelial dysfunction and angiogenesis: what is missing from COVID-19 and cannabidiol story? J Cannabis Res 2022;4. [DOI: 10.1186/s42238-022-00129-w] [Reference Citation Analysis]
4 Janecki M, Graczyk M, Lewandowska AA, Pawlak Ł. Anti-Inflammatory and Antiviral Effects of Cannabinoids in Inhibiting and Preventing SARS-CoV-2 Infection. IJMS 2022;23:4170. [DOI: 10.3390/ijms23084170] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Pagano C, Navarra G, Coppola L, Avilia G, Bifulco M, Laezza C. Cannabinoids: Therapeutic Use in Clinical Practice. IJMS 2022;23:3344. [DOI: 10.3390/ijms23063344] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
6 Wang B, Li D, Fiselier A, Kovalchuk I, Kovalchuk O. New AKT-dependent mechanisms of anti-COVID-19 action of high-CBD Cannabis sativa extracts. Cell Death Discov 2022;8. [DOI: 10.1038/s41420-022-00876-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
7 Guo M, Chen H, Dong S, Zhang Z, Luo H. CRISPR-Cas gene editing technology and its application prospect in medicinal plants. Chin Med 2022;17:33. [PMID: 35246186 DOI: 10.1186/s13020-022-00584-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Lopera V, Rodríguez A, Amariles P. Clinical Relevance of Drug Interactions with Cannabis: A Systematic Review. J Clin Med 2022;11:1154. [PMID: 35268245 DOI: 10.3390/jcm11051154] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Mueller JK, Riederer P, Müller WE. Neuropsychiatric Drugs Against COVID-19: What is the Clinical Evidence? Pharmacopsychiatry 2022;55:7-15. [DOI: 10.1055/a-1717-2381] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Hussain T, Jeena G, Pitakbut T, Vasilev N, Kayser O. Cannabis sativa research trends, challenges, and new-age perspectives. iScience 2021;24:103391. [PMID: 34841230 DOI: 10.1016/j.isci.2021.103391] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
11 Saraswat A, Vartak R, Patki M, Patel K. Cannabidiol Inhibits In Vitro Human Liver Microsomal Metabolism of Remdesivir: A Promising Adjuvant for COVID-19 Treatment. Cannabis Cannabinoid Res 2021. [PMID: 34918945 DOI: 10.1089/can.2021.0109] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
12 Chapman RL, Andurkar SV. A review of natural products, their effects on SARS-CoV-2 and their utility as lead compounds in the discovery of drugs for the treatment of COVID-19. Med Chem Res 2021;:1-12. [PMID: 34873386 DOI: 10.1007/s00044-021-02826-2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
13 Mahmud MS, Hossain MS, Ahmed ATMF, Islam MZ, Sarker ME, Islam MR. Antimicrobial and Antiviral (SARS-CoV-2) Potential of Cannabinoids and Cannabis sativa: A Comprehensive Review. Molecules 2021;26:7216. [PMID: 34885798 DOI: 10.3390/molecules26237216] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
14 Kicman A, Pędzińska-Betiuk A, Kozłowska H. The potential of cannabinoids and inhibitors of endocannabinoid degradation in respiratory diseases. Eur J Pharmacol 2021;911:174560. [PMID: 34648805 DOI: 10.1016/j.ejphar.2021.174560] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
15 Corpetti C, Del Re A, Seguella L, Palenca I, Rurgo S, De Conno B, Pesce M, Sarnelli G, Esposito G. Cannabidiol inhibits SARS-Cov-2 spike (S) protein-induced cytotoxicity and inflammation through a PPARγ-dependent TLR4/NLRP3/Caspase-1 signaling suppression in Caco-2 cell line. Phytother Res 2021. [PMID: 34643000 DOI: 10.1002/ptr.7302] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
16 Crippa JAS, Pacheco JC, Zuardi AW, Guimarães FS, Campos AC, Osório FL, Loureiro SR, Dos Santos RG, Souza JDS, Ushirohira JM, Ferreira RR, Mancini Costa KC, Scomparin DS, Scarante FF, Pires-Dos-Santos I, Mechoulam R, Kapczinski F, Fonseca BAL, Esposito DLA, Passos ADC, Dal Fabbro AL, Bellissimo-Rodrigues F, Arruda E, Scarpelini S, Andraus MH, Nather Junior JC, Wada DT, Koenigkam-Santos M, Santos AC, Busatto Filho G, Hallak JEC. Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Cannabis Cannabinoid Res 2021. [PMID: 34619044 DOI: 10.1089/can.2021.0093] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
17 Cárdenas-Rodríguez N, Bandala C, Vanoye-Carlo A, Ignacio-Mejía I, Gómez-Manzo S, Hernández-Cruz EY, Pedraza-Chaverri J, Carmona-Aparicio L, Hernández-Ochoa B. Use of Antioxidants for the Neuro-Therapeutic Management of COVID-19. Antioxidants (Basel) 2021;10:971. [PMID: 34204362 DOI: 10.3390/antiox10060971] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]